Chugai deal with NCC for Asian international collaborative prospective study A-TRAIN

Japanese drug major Chugai Pharmaceutical (TYO: 4519) today announced that it signed a joint research agreement with the Nation al Cancer Center Japan (NCC) and participated in an Asian multicenter prospective study A-TRAIN, which is led by NCC Hospital.

A-TRAIN is an international collaborative study to establish and analyze a database that combines genomic analysis using blood-based liquid biopsy test and clinical information, for six common intractable cancers which are frequently reported in Asia: cervical cancer, ovarian clear cell carcinoma, ovarian cancer, nasopharyngeal carcinoma, endometrial cancer and triple-negative breast cancer, said Chugai, which is majority-owned by Swiss pharma giant Roche (ROG: SIX).

The study aims to establish a foundation for personalized healthcare and to promote research and development of therapeutic agents, for intractable cancers which are frequently reported in Asia, by identifying genomic abnormalities that can be used as therapeutic targets and encouraging clinical trials. Chugai, in cooperation with Roche, provides a blood-based liquid biopsy test FoundationOne Liquid CDx Cancer Genomic Profile for genomic analysis in the ovarian cancer cohorts of this collaborative study.